Multiple targeted tyrosine kinase inhibition in the clinic: All for one or one for all?

European Journal of Cancer

Volumn 42, Issue 10, 2006, Pages 1351-1356

  de Jonge, M J A ^a   Verweij, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Combination; Development; Multi targeted; Tyrosine kinase inhibition

Indexed keywords

ALPHA INTERFERON; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; MIDAZOLAM; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; SORAFENIB; SUNITINIB; VANDETANIB;

ARTICLE; ASTHENIA; CANCER; CANCER PATIENT; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; PRIORITY JOURNAL; RASH; SIGNAL TRANSDUCTION; SKIN TOXICITY; TUMOR; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES;

EID: 33745155113     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.02.013     Document Type: Article

References (36)

1. Gschwind A., Fischer O.M., and Ullrich A. The discovery of receptor tyrosine kinase: targets for cancer therapy. Cancer 4 (2004) 361-370
2. Baselga J., and Arteaga C.L. Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. J Clin Oncol 23 (2005) 2445-2459
3. Herbst R.S., Fukuoka M., and Baselga J. Gefitinib- a novel targeted approach to treating cancer. Nature Rev 4 (2004) 956-965
4. Pao W., and Miller V.A. Epidermal Growth Facor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions. J Clin Oncol 23 (2005) 2556-2568
5. Kantarjian H., Sawyers C., Hochhaus A., et al. Haematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
6. van Oosterom A.T., Judson I.R., Verweij J., et al. Eur J Cancer 38 S (2002) S83-S87
7. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
8. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumours. J Clin Oncol 22 (2004) 3813-3825
9. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Results of mutation analysis in 377 patients entered into a randomized study. EJC, in press.
10. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
11. Arora A., and Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 3115 (2005) 971-979
12. Ryan A.J., and Wedge S.R. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92 (2005) 6-13
13. Hess-Stumpp H., Haberey M., and Thierauch K.-.H. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumour growth with high efficacy. Chaem Bio Chaem 6 (2005) 550-557
14. Milton D.T., Kris M.G., Azzoli C.G., et al. Phase I/II trial of gefitinib and RAD001 (Everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol (2005) abstract 7104
15. Smith R., Oliver S., Ghahramani P., et al. The effect of the CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of ZD6474 in healthy subjects. J Clin Oncol (2005) abstract 3124
16. Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol (2005), June 2005, 55, 6, 609-616.
17. Bello C., Hou B., Sherman L., et al. Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers. J Clin Oncol (2005) abstract 3078
18. Calvert H., Twelves C., Ranson M., et al. The effect of erlotinib (TarcevaTM) on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients - preliminary results. Proc Am Soc Clin Oncol (2005) abstract 3076
19. Fujisaka Y., Yamamoto N., Nokihara H., et al. Induction of Cytochrome P450 (CYP3A4) by Gefitinib in non-small lung cancer (NSCLC) patients. Proc Am Soc Clin Oncol (2005) abstract 3027
20. Holden S.N., Eckhardt S.G., Basser R., et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signalling, in patients with solid, malignant tumours. Ann Oncol 16 (2005) 1391-1397
21. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumour activity of SU11248, a novel oral multitargeted tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
22. Stadler W.M. Targeted agents for the Treatment of Advanced Renal Cell Carcinoma. Cancer ;104 (2005) 2323-2333
23. Raymond E., Faivre S., Vera K., et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 22 (2003) 769
24. Rosen L., Mulay M., and Long J. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumours. Proc Am Soc Clin Oncol 22 (2003) 765
25. Demetri G.D., George S., Heinrich M.C., et al. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumour (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol (2003) abstract 3273
26. Manning W.C., Bello C.L., Deprimo S.E., et al. Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients (pts) with imatinib-resistant gastrointestinal stromal tumour (GIST). Proc Am Soc Clin (2003) abstract 768
27. O'Farrell A.M., Foran J.M., and Fiedler W. An Innovative Phase I Clinical Study Demonstrated Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients. Clin Cancer Res 9 (2003) 5465-5476
28. Miller K.D., Trigo J.M., Wheeler C., et al. A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer. Clin Cancer Res 11 (2005) 3369-3376
29. Wilhelm S.M., Carter C., and Tang L. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res. 64 19 (2004) 7099-7109 Oct 1
30. Strumberg D., Richly H., Hilger R.A., et al. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumours. J Clin Oncol 23 5 (2005) 965-972 Feb 10
31. Ratain M.J., Eissen T., Stadler W.M., et al. Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol (2005) abstract no. 4544
32. Escudier B., Szczylik C., Eisen T., et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-90006) in patients with advanced renal cell carnicoma (RCC). Proc Am Soc Clin Oncol (2005) abstract LBA4510
33. Escudier B., Szczylik C., Eisen T., et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer 3 supplement (2005) 226 abstract 794
34. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
35. Motzer R.J., Rini B.I., Michaelson M.D., et al. Phase II trials of SU11248 show antitumour activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol (2005) abstract 4508
36. Demetri G.D., van Oosterom A.T., Blackstein M., et al. Phase III, multicenter, randomized, double-blind, placebo controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol (2005) abstract 4000